Compare KULR & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KULR | INO |
|---|---|---|
| Founded | 2013 | 1979 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | Electrical Products | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8M | 118.9M |
| IPO Year | 2016 | 1999 |
| Metric | KULR | INO |
|---|---|---|
| Price | $2.74 | $1.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $40.00 | $9.00 |
| AVG Volume (30 Days) | ★ 910.8K | 686.0K |
| Earning Date | 01-01-0001 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | $1,274,028.00 | ★ $42,220,086.00 |
| Revenue This Year | $64.40 | N/A |
| Revenue Next Year | $105.13 | $23,060.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $0.73 | $1.30 |
| 52 Week High | $7.49 | $2.86 |
| Indicator | KULR | INO |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 44.82 |
| Support Level | $2.62 | $1.48 |
| Resistance Level | $3.16 | $1.78 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 8.33 | 1.32 |
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.